The Short Version
Anktiva (nogapendekin alfa inbakicept) is approved only for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, as confirmed by the FDA, EMA, and all major clinical references. It is not approved for any other cancer type. While early-phase trials have explored its use in other malignancies, no regulatory body has recognized it as effective for treating, curing, or preventing "all types of cancer." The claim dramatically overstates both the drug's approved scope and its demonstrated efficacy.